Lipidomics for diagnosis and prognosis of pulmonary hypertension

Natalie Bordag[1,2,3,15], Bence Miklos Nagy[2], Elmar Zügner[4], Helga Ludwig[5], Vasile Foris[2,6], Chandran Nagaraj[2,15], Valentina Biasin[2,7], Ulrich Bodenhofer[5], Christoph Magnes[4], Bradley A. Maron[8], Silvia Ulrich[9], Tobias J. Lange[10,11], Konrad Hötzenecker[12], Thomas Pieber[3,13,15], Horst Olschewski[2,6,15*], Andrea Olschewski[2,14,15]

Affiliations

[1]Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.

[2]Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.

[3]CBmed GmbH, Center for Biomarker Research in Medicine, Graz, Austria.

[4]Institute for Biomedical Research and Technologies (HEALTH), Joanneum Research Forschungsgesellschaft m.b.H, Graz, Austria.

[5]School of Informatics, Communications, and Media, University of Applied Sciences Upper Austria, Hagenberg, Austria.

[6]Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

[7]Division of Physiology, Otto Loewi Research Centre, Medical University of Graz, Graz, Austria.

[8]Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

[9]Clinic of Pulmonology, University and University Hospital of Zurich, Zürich, Switzerland.

[10]Department of Internal Medicine II, Pulmonology and Critical Care, Kreisklinik Bad Reichenhall, Bad Reichenhall, Germany.

[11]Faculty of Medicine, University of Regensburg, Regensburg, Germany.

[12]Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

[13]Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz Austria.

[14]Experimental Anaesthesiology, Department of Anaesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria.

[15]BioMedTech, Graz, Austria.

*to whom correspondence should be addressed:

Prof. Horst Olschewski, Horst.Olschewski@medunigraz.at

Abstract

Pulmonary hypertension (PH) is a severe hemodynamic, progressive condition associated with high morbidity and mortality where early and less invasive diagnostics could crucially improve management. There is a need for biomarkers in PH that are functional, diagnostic, and prognostic. We used a broad metabolomics approach with machine learning analysis and specific free fatty acid (FFA)/lipid-ratios to develop diagnostic and prognostic PH biomarkers.

In a training cohort of 74 PH patients, 30 disease controls without PH, and 65 healthy controls, we identified diagnostic and prognostic markers that were validated in an independent cohort of 64 subjects. Markers based on lipophilic metabolites were more robust than those based on hydrophilic metabolites. FFA/lipid-ratios provided excellent diagnostic accuracy for PH with an AUC of up to 0.89 and 0.90 in the training and the validation cohorts, respectively. The ratios provided age-independent prognostic information and a combination of a ratio with established clinical scores increased the hazard ratio (HR) for FPHR4p and COMPERA2 from 2.5 to 4.3 and from 3.3 to 5.6, respectively.

Pulmonary arteries (PA) of idiopathic PAH (IPAH) lungs show lipid accumulation and altered expression of lipid homeostasis-related genes that may explain this accumulation. Our functional studies in PA endothelial and smooth muscle cells have shown that increased FFA levels caused excessive proliferation and PA endothelial barrier dysfunction, both hallmarks of pulmonary artery hypertension (PAH).

In conclusion, lipidomic changes in PH provide novel diagnostic and prognostic biomarkers and may point to new metabolic therapy targets.

Keywords

Abbreviations

6MWD, six minute walking distance; ACh, Acetylcholine; ADMA, asymmetric dimethylarginine; AUC, area under the curve; BH, Benjamini–Hochberg; BMI, body mass index; BNP or NT-proBNP, natriuretic peptide levels; CO, cardiac output; COPD, chronic obstructive pulmonary disease; CI, cardiac index; CTEPH, chronic thromboembolic pulmonary hypertension; DC, diseased control (non-PH); DLCOcVA, diffusing capacity for carbon monoxide alveolar volume, hemoglobin corrected; ECAR; extracellular acidification rate; ECIS, electrical cell-substrate impedance sensor; FEV1, forced expiratory volumet 1 s; FVC, forced vital capacity; FFA, free fatty acids; H&E, hematoxylin-eosin; HC, healthy control; HILIC, hydrophilic interaction liquid chromatography; hPAEC, human pulmonary artery endothelial cells; hPASMC, human pulmonary artery smooth muscle cells; HILIC, hydrophilic interaction liquid chromatography; HR, hazard ratio; HRMS, high resolution mass spectrometry; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; iPCA, independent principal component analysis; IVD, *in vitro* diagnostics; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LV, left ventricle; MAD, median absolute deviation; mPAP, mean pulmonary arterial pressure; MS, mass spectrometry; OCR; oxygen consumption rate; OPLS-DA, orthogonal projections to latent structures discriminant analysis; PA, pulmonary arteries; PAH; pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PBS, phosphate-buffered saline; PC, phosphatidylcholine; PDGF, platelet-derived growth factor; PH, pulmonary hypertension; PPP, pentose phosphate pathway; PVR, pulmonary vascular resistance; QC, pooled from samples for quality control; RAP, right atrial pressure; RDW, red cell distribution width; RF, random forest; RHC, right heart catheterization; ROC, receiver operator curve; RT, room temperature (20 – 25 °C); SEM, standard error of mean; SM, sphingomyelin; SMA, smooth muscle actin; SvO2, mixed venous oxygen saturation; TAG, triacylglyceride; TEER, transendothelial electrical resistance; TLC, total lung capacity; VWF, von-Willebrand Factor; WHO FC, World Health Organization functional class; WU, wood unit; XGBoost, eXtreme Gradient Boosting;

Introduction

Pulmonary hypertension (PH) affects 1% of the world's population[1,2] and thus represents a significant global health problem. Even mild PH is a strong negative prognosticator in patients with left heart disease[3], lung disease[4], and pulmonary arterial hypertension (PAH)[5,6].

In recent decades, global research efforts have led to targeted therapies for the rare pulmonary vascular diseases PAH and chronic thromboembolic PH (CTEPH) caused by blood clots in the lung. Despite this, the estimated five-year survival rate for newly diagnosed PAH patients stagnates at only 61%[7,8].

Diagnosis of PH is challenging because measurement of pulmonary arterial pressure (PAP) requires right heart catheterization (RHC), whereas non-invasive methods provide only estimates of PAP[1] or are not widely available[9]. Natriuretic peptide levels (BNP or NT-proBNP) are the only recommended biomarker for PH, but they are not specific and even higher levels can be found in left ventricular (LV) diseases. Therefore, the development of new diagnostic tools for the detection of PH, risk stratification, and epidemiological studies remains an important issue[2].

Fibroproliferative remodelling of distal pulmonary arterioles drives elevation in pulmonary artery pressure and pulmonary vascular resistance in PH. This sequence is associated with unique metabolic changes as detected from plasma and magnetic resonance imaging studies[10–15] and vascular cells and matrix that increase the biomass of the vessel wall[16], which may be due to tryptophan, glutamine, and proline metabolites as well as changes in the lipid profile. Our hypothesis was that PH patients develop a characteristic metabolic profile that enables detection and risk stratification in PH groups 1, 2, 3 and 4 (ESC/ERS guidelines)[1]. We identified a unique lipidomic profile in a diverse PH cohort against healthy and diseased controls which was confirmed in an independent validation cohort. In addition, we show that the small pulmonary arteries (PA) are strongly affected by such lipidomic changes.

Results

Clinical and cardiopulmonary hemodynamic characteristics for the study cohorts

Our study included three classes of subjects: PH patients, healthy control subjects (HC) and lung disease controls (DC) without PH, all of whom underwent blood-based high resolution mass spectrometry (HRMS)-based metabolomics (see Fig. 1). PH patients had a mean PAP (mPAP) ≥ 25 mmHg and were either 1) PAH, 2) PH due to left heart disease (LV), 3) PH due to lung disease, or 4) CTEPH. All DC had mPAP < 25 mmHg with either metabolic syndrome, chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The distributions in sex and body mass index (BMI) between PH and HC/DC were similar (see Fig. 1C). Age was in the same range, although controls tended to be younger. Metabolites were not significantly correlated with age (see Fig. S3).

Fig. 1. Study overview for all cohorts. (A) Schematic workflow of metabolomics measurement and computational analysis. Created with BioRender.com. **(B)** Schematic overview of group distribution of all included patients (n = 233) in training and validation cohorts. **(C)** Scatter plot of BMI vs. age (shape of symbols by sex) in the training cohort with distribution histograms per PH and per HC/DC showing comparable distributions of sex and BMI in PH and HC/DC, avoiding potential confounders by design.

The training cohort consisted of PH patients, DC and HC, all sampled in Graz, Austria. The external validation cohort contained PH patients and HC from Zürich, Switzerland and Regensburg, Germany. Patient characteristics are summarized in Table 1.

Table 1: Patients' characteristics (medians ± 95% confidence interval)

	Training (n=169)			Validation (n=64)	
	HC (n=65)	DC (n=30)	PH (n=74)	HC (n=7)	PH (n=57)
Age, years	58.0±2.8	59.5±4.7	66.5±3.0	42.0±13.8	57.0±3.7
Female:male (ratio)	44:21 (2.1:1)	20:10 (2.0:1)	50:24 (2.1:1)	5:2 (2.5:1)	43:14 (3.1:1)
BMI (kg/m²)	24.1±0.9	26.2±3.0	25.9±1.1	21.0±1.7	26.3±1.4
Diagnosis (since years)	-	4.5±2.0	1.0±1.2	-	2.0±1.7
Pulmonary hemodynamics from RHC					
mPAP (mmHg) mean pulmonary arterial pressure	-	-	42.0±2.5	-	50.0±3.9
PAWP (mmHg) pulmonary arterial wedge pressure	-	-	10.0±1.3	-	9.0±0.9
CO (L/min) cardiac output	-	-	4.3±0.4	-	4.2±0.4
CI (L/min/m²) cardiac index	-	-	2.6±0.2	-	2.4±0.2
PVR (WU) pulmonary vascular resistance	-	-	7.1±1.0	-	9.1±1.7
RAP (mmHg) right atrial pressure	-	-	6.0±1.2	-	7.5±1.1
Clinical data					
6MWD (m) 6-min walk distance	-	454±41	330±34	-	403±28
WHO FC world health organisation functional class	-	2.0±0.2	3.0±0.2	-	2.0±0.2
FEV1 (% predicted) forced expiratory volume 1 s	-	51.5±9.9	75.0±5.6	-	82.2±3.0
FVC (% predicted) forced vital capacity	-	63.8±6.7	82.8±5.5	-	91.4±4.0
FEV1/FVC (% predicted)	-	56.3±8.5	74.4±3.0	-	75.7±2.1
TLC (% predicted) total lung capacity	-	103.0±10.8	94.0±3.9	-	96.5±3.5
DLCO cSB (% predicted) single-breath CO diffusing capacity, haemoglobin corrected	-	49.6±7.8	63.8±6.0	-	53.8±3.9
DLCO cVA (% predicted) diffusing capacity for CO alveolar volume, haemoglobin corrected	-	70.0±7.9	69.6±6.1	-	62.0±3.7
RDW (%) red cell distribution width	-	14.0±0.7	15.4±0.7	-	14.7±0.6
NT-proBNP (pg/mL)	-	90±41	869±806	-	751±475
Uric acid (mg/dL)	-	5.0±0.5	6.0±0.6	-	6.6±0.7
Creatinine (mg/dL)	-	0.80±0.09	1.02±0.12	-	1.00±0.23
Bilirubin total (mg/dL)	-	0.40±0.13	0.64±0.13	-	0.65±0.16

Identification of a characteristic lipidomics profile in pulmonary hypertension

The metabolome of patients was assessed with untargeted hydrophilic interaction liquid chromatography (HILIC)-HRMS from serum, EDTA, and heparin plasma samples in four measurement

runs. As is typical with mass spectrometry (MS) based metabolomics methods, notable batch effects
occurred between runs as well as drift within the longer runs (see Fig. S2). Drift correction was
successfully performed (see Fig. S2) using quality control (QC) injections, which are a mix of equal
sample volumes repeatedly measured to monitor instrument stability.

In total, 164 known metabolites were of consistent analytical quality suitable for multivariate
and univariate exploratory analysis. Global metabolic changes were first examined using the
unsupervised multivariate method independent principal component analysis (iPCA). The metabolomes
of the PH patients differed from the control groups (HC and DC), which was visible as a clear group
separation in the iPCA scores plot along the first component (x-axis, Fig. 2A). The observed metabolic
difference was mainly driven by an increase in specific FFA in PH patients (Fig. 2B). The machine
learning method orthogonal projections to latent structures discriminant analysis (OPLS-DA)
confirmed that the observed global metabolic differences between PH and HC/DC were significant
($p < 0.001$, cross-validation and 1000 random permutations, Fig. 2C).

Fig. 2. PH is associated with a strong metabolic shift in the training cohort. (A) iPCA scores plot representing the metabolic profile of each subject as a dot. The proximity of the dots indicates the similarity of the subjects' metabolomes. Clear group separation by PH is visible along the first component. **(B)** Loadings plot corresponding to scores plot in (A). Each dot represents the contribution of the metabolite to the group separation observed in the scores plot. FFAs (yellow circles) strongly drive the group separation and are increased in PH patients. **(C)** OPLS-DA maximizes the group difference from PH to HC/DC and the resulting scores plot represents, as in A, the metabolome of each subject. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. The difference between the metabolome of PH and HC/DC was significant ($Q^2 > 50\%$, $p < 0.001$ from 1000 random permutation). **(D)** Volcano plot of univariate analysis showing significant ($p_{BH} < 0.05$, grey horizontal line) and strong (absolute contrast ratio > 0.25, grey vertical lines) increase in FFAs (yellow triangles). For all methods A-D, 164 known metabolites from the training cohort samples (n = 169) were used (drift corrected, log_{10}-transformed data). Colors as in B.

137 The univariate statistical analysis confirmed that FFAs were strongly and significantly
138 increased in PH compared with HC/DC (Fig. 2D). The few metabolites from routine clinical chemistry,
139 e.g. uric acid, were strongly correlated with their respective HILIC-HRMS metabolites (Fig. S3). FFAs

140 and lipids were not strongly correlated with any clinical parameters known to be relevant to PH,
141 suggesting that the detected FFA changes may be independent from conventional clinical assessment.

FFA/lipid-ratios diagnose pulmonary hypertension

The potential of using metabolites to diagnose PH was first investigated with the machine
learning method random forest (RF)[17,18] and extreme gradient boosting (XGBoost)[19]. From the 164
metabolites, 11 were excluded from biomarker analysis because of low signal intensities and high noise
(see Supplementary Data 1). RF and XGBoost both achieved an area under the curve (AUC) of 0.83 in
the receiver operator curve (ROC) analysis in the validation set (Fig. 3A and Fig. S4). The drift
correction used here allowed a joint exploratory statistical analysis, but drift correction is impossible in
future routine clinical diagnostics. Therefore, all the diagnostic and prognostic performance was also
tested without drift correction. RF and XGBoost performance were almost equivalent without drift
correction, indicating that their nonlinear algorithms exhibit intrinsic drift-handling capabilities (Fig.
S4).

To find a technically simplified biomarker for PH, all metabolites were grouped according to
their chemical properties into hydrophilic metabolites and lipophilic FFAs & lipids. The performance
of hydrophilic metabolites alone was lower than that of FFAs & lipids alone. When all metabolites or
only the hydrophilic metabolites were used, the AUC of RF and XGBoost results dropped notably from
model training towards the external validation, regardless of the drift correction (Fig. 3B, C and Fig.
S4). However, for lipophilic metabolites, the AUC was much more consistent between training and
validation for both RF and XGBoost, suggesting that lipophilic metabolites were less susceptible to
technical problems and overfitting. Other important model performance parameters such as specificity,
sensitivity, and balanced accuracy were comparable for RF and XGBoost irrespective of drift correction
or metabolite selection (Fig. 3C). For RF and XGBoost, the average balanced accuracy was 71.5% and
70.6%, respectively, the specificity was 84.8% and 85.9%, respectively, and the sensitivity was 54%
and 50.7%, respectively (Fig. S4).

Fig. 3. Diagnostic accuracy for PH in training and validation cohorts. (A) ROC plots within the training cohort (n = 169, solid lines) and the validation cohort (n = 64, dashed lines) with their 95% confidence intervals as ribbons. For modelling, the training cohort was randomly split into 80% training and 20% testing data. The split was repeated five times without overlap of test data for cross-validation. RF used either all suitable 153 metabolites (left), only 50 hydrophilic metabolites (middle), or only 103 lipophilic metabolites (right) (drift corrected, log_{10}-transformed data). **(B)** The ROC plots of the three best FFA/lipid-ratios within the training cohort (n = 169, solid lines) and the validation cohort (n = 64, dashed lines) with their 95% confidence intervals as ribbons (drift corrected, log_{10}-transformed data). **(C)** Plot of model performance metrics sensitivity, specificity and balanced accuracy for RF, XGBoost, and the three best FFA/lipid-ratios when based on either training (circles) or validation (diamonds)

cohorts only or all available data (squares). The performance of RF and XGBoost was comparable for all three metabolite subsets with and without drift correction (both log_{10}-transformed). The performance of the three best FFA/lipid-ratios was more stable and balanced than of RF or XGBoost.

Next, we tested whether ratios built from lipophilic metabolites could replace machine learning
approaches to create an explainable, easy-to-measure marker with selected FFAs in the numerator and
selected lipids in the denominator. The FFAs in the numerator were selected based on their analytical
performance and statistical significance in PH versus HC/DC. The denominator was chosen to correct
for inter-personal differences in lipid metabolism using lipids without statistical significance in PH
versus HC/DC. For the nominator, 11 FFA were considered: FFA C15:0 (pentadecylic acid),
FFA C16:2 (palmitolinoleic acid), FFA C16:1 (palmitoleic acid), FFA C17:1 (heptadecenoic acid),
FFA C17:0 (margaric acid), FFA C18:3 (α-linolenic acid, ALA, or γ-linolenic acid, GLA), FFA C18:2
(linoleic acid, LA), FFA C18:1 (oleic acid), FFA C19:1 (nonadecenoic acid), FFA C20:5
(eicosapentanoic acid, EPA) and FFA C20:1 (eicosenoic acid). Eight lipids were considered for the
denominator: lysophosphatidylcholine (LPC) 18:2, LPC 18:1, phosphatidylcholine (PC 36:4, PC 38:6),
sphingomyelin (SM 34:2, SM 36:2), lysophosphatidylethanolamine (LPE) 16:0, and LPE 18:1. To
stabilize the ratios we also tested sums of up to six FFAs in the numerator and up to four lipids in the
denominator limiting the maximum number of individual metabolites in a given ratio to ten.

In total, about a quarter of a million FFA/lipid-ratios were created when systematically testing
all possibilities with ROC analysis. Most FFA/lipid-ratios achieved moderate to high performance with
AUCs above 0.8 (Fig. 3 and Fig. S5). In comparison, the diagnostic performance of each FFA was much
weaker with AUCs below 0.7. The diagnostic performance of the FFA/lipid-ratios was independent of
drift correction, making the FFA/lipid-ratios suitable for stand-alone routine measurements (Fig. S5).

There may be a concern that combining multiple metabolites in a ratio increases technical error
and impairs reproducibility. However, in our cohort, the calculated technical variability according to
the laws of error propagation was <5% for most FFA/lipid-ratios and <10% for all others (Fig. S5G).

For simplicity, the top three performing ratios were selected as examples by their performance
(highest AUC, sensitivity, specificity) and named RATIO1, RATIO2, and RATIO3 (Fig. S5). These
three ratios had six metabolites in common: numerator (FFA C20:1 + FFA C16:1 + FFA C15:0);
denominator (PC 38:4 + PC 36:4 + LPC 18:1). The only difference to RATIO1 was the addition of two
more FFA to the numerator sum (either FFA 18:3 + FFA 17:0 or FFA 18:2 + FFA 17:0, Fig. 3B) in
RATIO2 and RATIO3. The ROC curves of RATIO1-3 overlapped well between training and validation
cohort (Fig. 3B). All other important performance parameters were also very similar between RATIO1-
3 (Fig. 3C) and notably outperformed all machine learning models, irrespective of drift correction,
especially in terms of sensitivity with an average balanced accuracy of 85.5%, a specificity of 89.7%
and a sensitivity of 81.4% (Fig. 3C).

FFA/lipid-ratios massively reduce technical complexity compared to broad metabolomics runs
while achieving better diagnostic performance than machine learning approaches. Accordingly, we
believe that such FFA/lipid-ratios are suitable for future routine applications.

Specific FFA/lipid-ratios predict survival

The prognostic value of our RATIO1 was compared with well-established invasive and non-
invasive scores: FPHR4P[20] and COMPERA2[1,21]. Survival and hazard ratios (HR) were investigated for
all PH patients and patients with non-PH lung disease (COPD, ILD). For direct comparability of
Kaplan-Meier survival curves and HRs all numeric values were categorized into low or high risk
according to their optimal cut-off points (e.g. age 58 years).

We analysed two different survival times, one since sampling (ie, time of enrolment = baseline)
and one since PH diagnosis. Survival time since baseline was available for 129 PH and 21 DC (13
COPD, 8 ILD) patients, and time since diagnosis was available for 118 PH and 21 DC patients. The
COMPERA2 score was available for 121 PH and 20 DC patients, and the FPHR4p for 91 PH and 20
DC patients for times since baseline.

As expected, FPHR4p and COMPERA2 scores were significantly associated with survival time
since baseline (Fig. 4) and since diagnosis (Fig. S6). RATIO1 was also significantly associated with
survival (Fig. 4) with a similar HR to COMPERA2 scores. When RATIO1 was combined with each of
the scores (RATIO1 and score equally weighted), the prognostic value of the respective score improved
notably (Fig. 4). This indicates that our simple metabolomic marker provides independent prognostic
information and would complement established prognostic scores.

Next, we examined the major confounding factors age, sex and BMI. The HR for age alone was
significant for both survival since baseline and survival since diagnosis (Fig. S7). The HR for BMI
alone was only slightly elevated, whereas the HR for male sex was not significant. A joint model with
all three confounders showed that only age remained significant. Therefore, we included only age as
covariate to HR analysis of our RATIOs and the ratios and FPHR4p and COMPERA2 scores (Fig. S7).

Fig. 4. RATIO1 predicts survival and improves prediction of established clinical scores. **(A)** Cox HR analysis for survival from baseline and 95% confidence intervals with statistical significance coded as not significant, (ns); * p < 0.05; ** p < 0.01; *** p < 0.001. Combining RATIO1 with FPHR4P or COMPERA2 increased HR compared with scores or RATIO1 alone. **(B, C, D)** Kaplan–Meier curves of survival from baseline by RATIO1 **(B)**, FPHR4p and COMPERA2 **(C)** and RATIO1 combined with FPHR4p or COMPERA2 **(D)**. All cut-offs were optimized with maxstat for both Cox HR analysis and Kaplan–Meier analysis. RATIO1 was based on log_{10}-transformed data without drift correction. RATIO1 and scores were combined scaled 0 to 1 to give equal weighing. FPHR4p was inverted so that higher scores also represent higher risk as in COMPERA2 for simpler interpretation.

The HR of RATIO1 remained similar and significant after correction for age (Fig. 4A). In
contrast, correction for age decreased the respective HR for both FPHR4p and COMPERA2. This
indicates that both FPHR4p and COMPERA2 scores may be are more age-dependent than RATIO1.

Finally, established clinical risk factors and single metabolites were analysed with respect to
survival. Higher World Health Organization functional class (WHO FC), lower 6MWD, higher NT-
proBNP and higher uric acid levels were associated with poorer survival (Fig. S8A). Survival analysis
of each metabolite revealed that many metabolites were moderately associated with survival
(0.05 < p < 0.01), but, with a much lower HR than FPHR4P, COMPERA2 or RATIO1. However, some
metabolites strongly predicted survival, e.g. asymmetric dimethylarginine (ADMA) and
N-acetylputrescine (Fig. S8A), which are well-known prognosticators in other diseases[22–24].

Changes in lipid metabolism in pulmonary arteries of idiopathic PAH (IPAH) patients

Because of the strong association between the lipidomics profile with PH, we investigated small PA from IPAH patients (transplant recipients) and healthy donor lungs from explanted lungs. Oil red O staining and co-staining with markers of endothelial and smooth muscle cells showed accumulation of lipids in several IPAH PA (Fig. 5A). The observed lipid deposition could be the result of increased uptake of fatty acids, dysregulation of fatty acid metabolism, or increased lipid synthesis. The observed lipid deposition could be the result of increased uptake of fatty acids, dysregulation of fatty acid metabolism, or increased lipid synthesis. Therefore, we performed laser-capture microdissection of small PA ($< 500 \, \mu m$) from IPAH patients and healthy donors and examined gene expression of transporters and enzymes related to lipid metabolism. Gene expression showed significant upregulation of several key genes involved in lipid metabolism in IPAH (Fig. 5B). Most striking was the significant upregulation of SLC27A5, GAPT1, AGAPT1, Lipin2 and DGAT1 in IPAH. DGAT1 plays a critical role in lipid droplet formation. Up-regulation of the FFA transport protein SLC27A5 indicates increased uptake of FFAs from the circulation. GPAT, AGPAT, and lipin family enzymes promote triglyceride biosynthesis, incorporation of exogenous fatty acids into triacylglycerides (TAG) and phospholipids, as well as β-oxidation. The upregulation of these genes in the small PAs of IPAH patients might represent a compensatory mechanism for the increased circulating FFA levels or might be a manifestation of the primary disease mechanism.

Fig. 5. Presence of lipids and expression of lipid-metabolism genes in IPAH pulmonary arteries. (A) Visualization of endothelium (von-Willebrand factor, VWF) and smooth muscle cell layer (smooth muscle actin, SMA) together with oil red staining in human IPAH lung serial sections (scale bar: 50 μm). **(B)** Gene expression of lipid homeostasis-related enzymes in laser-capture microdissected human PA (n = 8-10 independent patients, respectively). Vertical lines represent means with standard error of mean (SEM). Red asterisks mark Mann Whitney test < 0.05.

Next, we mimicked elevated circulating FFA levels by treating primary human pulmonary
artery smooth muscle cells (hPASMC) and human pulmonary artery endothelial cells (hPAEC) from
healthy donors with a FFA cocktail. Bodypi fluorescence staining showed accumulation of fat at the
cellular level in hPASMCs and hPAECs (Fig. 6A). To better understand the functional effects on the
cellular level, we performed further in-vitro studies with primary hPAEC and hPASMCs. In hPASMCs,

the treatment with a mixture of FFAs significantly promoted cell proliferation (Fig. 6B), and in hPAECs

significantly decreased acetylcholine (ACh)-induced NO secretion (Fig. 6C).

Fig. 6. Effects of FFA treatment on hPASMC and hPAEC. (A) Representative Bodipy fluorescence staining of hPASMC and hPAEC in the absence (Ctrl) or presence of FFA (scale bar: 50 μm). **(B)** Platelet-derived growth factor (PDGF)-BB induced proliferation of primary hPASMC measured with thymidine incorporation, in the absence (Ctrl) or presence of FFA (n = 4). Changes are expressed as percentages compared with untreated controls (Ctrl). **(C)** ACh-induced NO production in primary hPAEC (n = 4). Changes are expressed as percentages compared with untreated controls (Ctrl). **(D)** TEER, as determined by electrical cell-substrate impedance sensor (ECIS), shows a significant increase in hPAEC treated with FFA. Representative original curve (left panel) and changes expressed as percent change compared with controls (Ctrl) (n = 4). **(E, F)** Summarized data from hPASMC and hPAEC using the Seahorse XFe24 Extracellular Flux Analyzer. All measurements were performed on n = 25,000–50,000 cells/well and five wells per cell type. Each experimental group consisted of two to three patient cell lines (samples). All data were normalized to total protein per well before analysis. Results are given as median with interquartile range. Mann Whitney test * < 0.05, **< 0.01, ***< 0.001.

We investigated the effect of increased FFA levels on endothelial barrier function by
determining the magnitude of thrombin-induced endothelial barrier dysfunction. Fig. 6D shows the
typical response of control endothelium to thrombin. When endothelial monolayers were pre-treated
with FFA they exhibited a significantly pronounced decrease in transendothelial electrical resistance
(TEER) and delayed recovery of barrier function compared to control media (Fig. 6D). These observed
effects upon FFA treatment all suggest increased barrier dysfunction. Finally, we examined FFA-
induced metabolic responses in hPASMCs and hPAECs and found significantly decreased coupling
efficiency in both cell types in response to FFA treatment (Fig. 6E, F). Moreover, FFA exposure
decreased non-mitochondrial respiration and ATP production in hPAEC and increased proton leak in
hPASMC. These results show that healthy hPASMCs and hPAECs, under FFA treatment, develop
phenotypic changes that have been described as characteristic of IPAH. This suggests that high
concentrations of circulating FFAs may deteriorate the maintenance function of the endothelium and
simultaneously cause dysfunction of the smooth muscle layer of the small PA, representing either a
primary cause or a novel vicious circle in PH.

272 Discussion

To our knowledge, this study is the first to apply unsupervised, broad metabolome analysis of
PH patients of group 1 to 4. The generated specific FFA/lipid-ratios accurately identified patients with
PH and predicted prognosis, independent of existing clinical prognostic scores and age. Their diagnostic
and prognostic value was validated in an independent international cohort. Furthermore, *in vitro*
mechanistic studies confirmed the disturbed lipid metabolism in PA of IPAH patients and the adverse
effects of elevated FFA on hPAEC and hPASMC homeostasis. Our simple FFA/lipid-ratios might be
useful in the diagnosis and clinical management of PH patients and might serve as surrogate end points
in future clinical trials.

Although there has been tremendous progress in the understanding of PAH in recent decades, there is still an unmet need for therapy. According to a recent literature review, the five-year survival rate for newly diagnosed patients has not significantly increased despite a multitude of approved PAH medications[8]. This may be due to the fact that the initial phase of the disease is clinically silent and sensitive diagnostic methods are missing. PAH affects all aspects of a person's daily life and has a major impact on quality of life, including physical activity, well-being and emotional and social functioning[25], where even a mild elevation in PAP may limit patients' exercise capacity and reduce life expectancy[1,5,6,26]. Thus, it is crucial to identify novel, simple biomarkers for early identification and risk stratification, preferably based on the cellular and molecular mechanisms underlying the disease, to determine prognosis, initiate treatment, and monitor response and long-term disease progression.

Spanning over two decades, extensive basic, translational, and clinical analyses have supported a causative link between metabolic reprogramming and PAH[27]. Similar to the Warburg effect in cancer, a shift from mitochondrial oxidation to glycolysis appears to occur in the right ventricle of PAH patients[28,29]. In this study, we show that the small PAs are also affected by significant metabolic changes. Taking cues from cancer, recent data demonstrate significant alterations in metabolic programs other than glycolysis and glucose oxidation, including the pentose phosphate pathway (PPP), glutaminolysis, lipolysis, fatty acid synthesis and oxidation and changes in the plasma proteome [12–16,30,31]. However, it remains unclear whether these changes originate in the overloaded right ventricle, in the primarily affected pulmonary vessels, or elsewhere.

In our cohort, severe metabolic perturbations were detected using an open metabolomics approach, but the most severe and consistent changes were found in FFAs. Classical machine learning using RF and XGboost showed that these metabolic differences held a high potential for diagnostic biomarkers. Furthermore, these approaches were able to overcome typical technical MS-specific problems such as batch effects and intensity jumps between measurements, which usually require drift correction. The performance of RF and XGBoost models was independent of drift correction which is obviously due to their nonlinear algorithms.

These strong metabolic perturbations are valuable for diagnostic and prognostic purposes, particularly in the form of an easily applicable FFA/lipid-ratio. In order to be implemented in routine, such diagnostics must deliver reliable results at all times independent of batch effects and drift corrections. However, since absolute quantitative methods are labour intensive and costly, we tested whether ratios of measured parameters provide an intra-sample normalization as a possible solution. We used ratios of selected FFAs and lipids with the rationale that lipid levels correct for both batch effects and inter-individual variability of patients' lipid metabolism and lifestyle. Technically, the similar polarity of lipids and FFAs should help reduce the complexity and cost of high-throughput measurements.

These FFA/lipid-ratios performed very well in both PH diagnosis and survival prediction and
were also independent of batch effects. The diagnostic performance of these FFA/lipid-ratios even
outperformed RF and XGBoost models, especially in sensitivity. In addition, the results were stable
despite the use of different sample types such as serum, heparin and EDTA plasma from three centres;
a very important factor for broad applicability in routine diagnostics. The FFA/lipid-ratios are easy to
use and fully explainable compared to machine learning models, which is advantageous for future
studies and regulatory approval processes for *in vitro* diagnostics (IVD).

Survival prediction is an important tool in the management of PAH patients. Several clinical
scores have been established, with FPHR4P and COMPERA2 representing most recent developments
derived from large databases[20,21]. The FPHR4P[20] score estimates prognosis based on WHO FC, 6MWD,
CI, and RAP, while COMPERA2[21] is based on non-invasive parameters (WHO FC, 6MWD, NT-pro-
BNP). In our cohort, both scores predicted survival but lost some predictive power when corrected for
age. In contrast, our RATIO1 predicted survival more independently of age. Most importantly, both
clinical scores gained predictive power when combined with RATIO1. Thus, FFA/lipid-ratios represent
an independent prognostic factor that combines favourably with established prognostic PH scores.

The uptake and metabolism of long-chain fatty acids is critical for many physiological and
cellular processes, and cellular accumulation may cause numerous pathological and functional changes.
Previous investigations of PAH have shown severe metabolic changes of the right ventricle and elevated
in vivo myocardial triglyceride content[10,28,29]. Our investigations add important information by showing
that small PA of IPAH patients were affected by lipid accumulation. Interestingly, we found increased
gene expression of enzymes responsible for fatty acid uptake and triglyceride biosynthesis in these
vessels (Fig. 5C). This could be caused by the high FFA levels in the circulation, however, it could also
represent a primary change in the cell physiology that deteriorates PH. The present data suggest that in
PH, the failing right ventricle is no longer able to metabolise FFAs, leading to an increase of circulating
FFA levels, which negatively affects pulmonary vascular cells. However, it is also possible that there
are primary changes in the lipid metabolism of the small PAs or elsewhere, which then lead to altered
cellular function, subsequently increasing right ventricular afterload and initiate a vicious circle in PH.

Numerous studies have indicated that the expression levels of GAPT1 / AGPAT1 / lipin-1 have
important cellular metabolic consequences[32–35]. This might explain some of the functional changes in
IPAH endothelial cells and hPASMC after FFA exposure compared with controls. For the first time,
we explored the effects of FFA exposure in primary human hPAECs and hPASMCs. FFA exposure
decreased NO secretion and impaired barrier function in hPAECs, while proliferation increased in
hPASMC. In addition, exposure to FFAs induced changes in non-mitochondrial respiration and
coupling efficiency in both cell types. These results provide evidence for impaired lipid handling in
IPAH PAs that might even trigger the remodelling in PAH.

Strengths of this study include the broad metabolomics approach, sampling and processing
conditions as in routine clinical practice, inclusion of a disease control group, comprehensive clinical
assessment, use of machine learning, development of diagnostic and predictive FFA/lipid-ratios, and
mechanistic studies in primary IPAH PA cells. The disadvantage of a comparatively modest number of
participants, particularly the number of controls in the validation cohort, was offset by well standardized
clinical characterization, including RHC, coupled with long follow-up times that enable survival
analysis.

Our blood samples were collected along with clinical routine blood draws, demonstrating that
it is not necessary to sample under strictly controlled conditions for obtaining specific FFA/lipid-ratios.
All metabolic measurements were based on high-resolution mass spectrometry, a very sensitive and
exact method, yet slow, expensive and work-intensive. However, our FFA/lipid-ratios were based on a
very simplified approach to characterize the metabolic derangement. The combination of
FFA/lipid-ratios with established FPHR4P and COMPERA2 scores was not optimized, since our main
focus was to find new, independent diagnostic and prognostic biomarkers but still provided clear results.

Future studies should include larger numbers of patients with a balanced group distribution and
more patients with early pulmonary hypertension with less impairment of right ventricular function.
Future longitudinal studies are also warranted to investigate the value of metabolic markers for patient
management.

370 Conclusions

371   Our FFA/lipid-ratio, based on overt lipid changes in PH patients, identified PH patients with a
372 high accuracy and was associated with prognosis. If implemented into the management strategy for PH
373 patients, this could inform therapy decisions to improve outcomes. Mechanistic insights into the
374 metabolic changes in small PA could identify new therapeutic targets.

Online Methods

Cohort Data Sources

Results from the Graz Pulmonary Hypertension Registry (GRAPH) have been reported previously[36,37]. Briefly, the program uses a software application linked to the electronic health record for documentation of all patients of the Division of Pulmonology at the Department of Internal Medicine of the Medical University of Graz who gave written informed consent. Demographic, clinical, echocardiographic, procedural, and hemodynamic data and blood samples are collected and tracked for longitudinal outcomes. All hemodynamics were measured in a standardized fashion by the same experienced team[36]. Regularly scheduled quality checks of the registry are performed to ensure completeness and accuracy. Written informed consent was obtained from all patients and the study was conducted in line with the Helsinki declaration. The study was approved by the institutional ethics board (identifier: 23-408ex10/11), and the study has been registered at ClinicalTrials.gov (NCT01607502).

The BioPersMed (Biomarkers of Personalised Medicine) project is designed as a single-centre, prospective, observational cardiovascular risk study. Between 2010 and 2016, 1022 community dwelling and asymptomatic individuals were regionally recruited and assessed biannually including a standardized biospecimen acquisition[38]. Written informed consent was obtained from all patients and the study was conducted in line with the Helsinki declaration.

Cohort Study Population

We retrospectively enrolled two consecutive cohorts of patients identified through our single-centre GRAPH registry and labelled them as GRAPH-Metabolomics (GRAPH-M).

The inclusion criteria for the first cohort were diagnosis of idiopathic pulmonary arterial hypertension (IPAH) and absence of severe co-morbidities. Healthy sex- and age-matched subjects served as a healthy controls (HC).

Inclusion criteria for the second cohort consisted of the following PH groups 1 – 4: 1) PAH, or 2) PH associated with heart disease, 3) PH associated with lung diseases (COPD, ILD), or 4) CTEPH. This cohort of disease controls (DC) consisted of patients with airway or parenchymal lung disease or patients with metabolic syndrome (hypertension, hypercholesterinemia and type 2 diabetes mellitus) but no signs of elevated PAP. Healthy sex- and age-matched subjects served as a control group (HC). The patients with the metabolic syndrome were selected from the BioPersMed cohort Graz.

All cohorts with the exception of patients with metabolic syndrome or HC underwent RHC. In patients who underwent multiple RHCs, the first RHC was considered the index procedure and was the only one included in the analysis. Patients were included in the analyses if data from a complete RHC were available, including a resting value for mPAP, PAWP, CO, heart rate, systolic and diastolic PA

408   pressure, PVR and mixed venous oxygen saturation (SvO_2). We used the standard equation to calculate

409   the pulmonary vascular resistance with PVR = (mPAP - PAWP)/CO expressed in WU.

Validation Cohort

This cohort comprised an international multicentric patient cohort. The inclusion criteria for the

validation cohort were the confirmed diagnosis of PAH and informed written consent at the home

institution. All participating centers were experienced centers of excellence for PH and all patients

underwent RHC in a standardized manner. Demographic, clinical, echocardiographic, procedural, and

hemodynamic data and blood samples were available as anonymized data. The sample collection was

approved by the local Ethics Committee in each local center (Regensburg University, ethics committee

No. 08/090 and cantonal ethical review board Zürich KEK 2010-0129; 2014-0214; 2017-0476).

Cohort Outcomes

419   The primary outcome was the confirmation of PH, defined as mPAP $\geq$ 25 mmHg according to

420   the ERS/ESC guidelines from 2015[39]. The secondary endpoints included time to all-cause mortality

421   with data provided by Statistic Austria (single-centre registry Graz) and by the respective centers who

422   contributed to the validation cohort. A complete list of covariates analyzed in this study is provided in

423   the Supplementary Material (Fig. S3).

Human lung tissue samples

Human lung tissue samples were obtained from patients with IPAH who underwent lung

transplantation at the Department of Surgery, Division of Thoracic Surgery, Medical University of

Vienna, Vienna, Austria. The protocol and tissue usage were approved by the institutional ethics

committee (976/2010) and written patient consent was obtained before lung transplantation. The patient

characteristics included: age at the time of the transplantation, weight, height, sex, mPAP measured by

RHC, pulmonary function tests, as well as the medical therapy. The chest computed tomography scans

and RHC data were reviewed by experienced pathologists and pulmonologists to verify the diagnosis.

Healthy donor lung tissue was obtained from the same source. Donor/IPAH patient characteristics are

given in Supplementary Material (Table S2).

Lung histological Oil Red O staining

The lipid accumulation of lung tissues was visualized by Oil Red O staining (Merck KGaA,

Darmstadt, Germany). Lung tissue was embedded in tissue freezing medium, were snap frozen at

$-80\,°C$ and sliced using a Leica CM 1900 cryostat (Leica Biosystems GmbH, Wetzlar, Germany) at a

thickness of 5μm per section. The slices were stained with Oil Red O working solution for 10 min,

differentiated in isopropanol for 5 min, and then washed with water at room temperature (20 – 25 °C)

(RT). The experiments were finished according to the manufacturer's instructions. The morphological

features of the tissues were assessed by hematoxylin-eosin (H&E) staining. The lipid in the tissue
observed by microscope.

Laser capture microdissection of PA and RNA extraction

444   Laser capture microdissection (LCM) of 10 donor lungs and 10 lungs from IPAH patients, as
445 well as mRNA isolation and cDNA synthesis were performed as previously described[40]. The intima and
446 media layers of PAs of 100 – 500 μm diameter were selected, marked and isolated with the Arcturus®
447 LCM System. Captured vessels were immediately transferred into RNA lysis buffer and were snap
448 frozen. RNeasy Micro Kit was utilized to isolate RNA (RNeasy Micro Kit, Qiagen, Hilden, Germany)[41].

qRT-PCR - laser capture microdissected human PA

The expression of enzymes and transporters was analyzed with real-time quantitative (qRT)-
PCR using the QuantiFast SYBR PCR reagent (Qiagen, Hilden, Germany) according to[42]. Primer pairs
(Eurofins, Graz, Austria), summarized in Supplementary Material (Table S3), were designed to span at
least one exon-exon boundary to avoid the amplification of genomic DNA. The specificity of all
primers, as well as the length of the amplicon, were confirmed by melting curve analysis and by running
the products on 2% agarose gels, respectively.

Cell Isolation and culture

hPAECs

hPAECs were either purchased from Lonza or isolated from donor lungs. For the isolation of
donor hPAECs, PA (< 2 mm in diameter) were isolated and the endothelium incubated with an
enzymatic mixture of collagenase, DNAse and dispaze in HBSS at RT[43]. Cell suspension was collected,
resuspended in VascuLife Complete SMC Medium and cultured in gelatin-coated T25 flasks at 37°C
and 5% CO_2. After reaching 70 – 80% confluency, cells were trypsinized, enriched by 3 consecutive
steps of CD31-selective magnetic-activated cell sorting technology and verified via morphological and
marker confirmation (smooth muscle actin SMA, fibronectin, vimentin, von-Willebrand Factor VWF,
smooth muscle myosin heavy chain and CD31). Surplus hPAECs were frozen (endothelial cell complete
medium containing 12% FCS and 10% DMSO) and stored in liquid nitrogen until further use. Passages
2–6 were used for the experiments. Detailed patient characteristics of isolated hPAECs can be found in
Supplementary Material (Table S4).

hPASMCs

The isolation and culture of human hPASMCs was performed as previously reported[44]. After
the removal of the endothelial cell layer, the media was peeled away from the underlying adventitial
layer and cut into approximately 1–2 mm^2 sections, centrifuged and resuspended in VascuLife

Complete SMC Medium supplemented with 20% FCS and 0.2% antibiotics, then transferred to T75

flasks and cultured at 37°C and 5% CO_2. After a confluent monolayer of hPASMC had formed, the

cells were trypsinized and either cultured in VascuLife Complete SMC medium supplemented with

10% FCS and 0.2% antibiotics, or frozen (VascuLife Complete SMC Medium containing 15% FCS and

10% DMSO) and stored in liquid nitrogen until further use. Passages 4–8 were used for the experiments.

Detailed patient characteristics of isolated hPASMCs can be found in Supplementary Material (Table

S4).

Lipid visualized by bodipy staining

BODIPY (D3922, Invitrogen, Carlsbad, Calif, USA) (excitation wavelength 493 nm, emission

maximum 503 nm), was diluted in phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 12

mM $HPO_4^{2-}/H_2PO_4^{-}$, pH 7.4) or DMSO at a concentration of 1 mg/mL and applied to the hPASMCs

and hPAECs for 20 mins at RT. Fixed cells (4% paraformaldehyde at 37°C for 5 mins) were used.

Following fixation, samples were washed 3 times in PBS for 10 mins. Sections were counterstained

with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) to visualize nuclei and

covered with glass cover slips. Images were taken using a laser scanning confocal microscope (Zeiss

LMS 510 META; Zeiss, Jena, Germany) with Plan-Neofluar (×40 /1.3 Oil DIC) objective.

Measuring cell metabolic state

Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined

by the Seahorse XFp analyzer (Agilent, USA)[45]. hPASMCs or hPAECs were plated onto cell culture

microplates on the day before the experiments and treated with 0.25mM FFA (a mix of oleate, FFA

16:0 and FFA C18 (2:1:1)) in VascuLife® complete Medium and incubated for 24 h. Cells were then

incubated in XF assay medium (Agilent), supplemented with 25 mmol/L glucose and 1 mmol/L

pyruvate (hPASMCs) or 10 mmol/L glucose, 1 mmol/L pyruvate, and 2 mmol/L L-glutamine (hPAECs)

for 1 h at RT before the measurement. After the recording of the basal rates of OCR and ECAR, final

concentrations of 1 μmol/L oligomycin, 1 μmol/L carbonyl cyanide-4 (trifluoromethoxy)

phenylhydrazone, and 0.5 μmol/L rotenone and antimycin A for human hPASMCs; 1 μmol/L

oligomycin, 1 μmol/L carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone, and 1 μmol/L rotenone

and antimycin A for human hPAECs were added (XF Cell Mito Stress Test Kit, Agilent) through the

instrument's injection ports to obtain proton leak, maximal respiratory capacity, and nonmitochondrial

respiration, respectively. Glycolytic capacity was measured using an XF Glycolysis Stress Test Kit

(Seahorse Bioscience). ECAR was determined after serial injection with 10 mmol/L D-glucose, 1

μmol/L oligomycin, and 100 mmol/L 2-deoxyglucose. All the assays were performed in triplicate and

normalized to protein content.

Endothelial Barrier Function

TEER served as an indicator of barrier function of endothelial cell monolayers. TEER was determined using an electrical cell-substrate impedance sensor (ECIS) (Applied Biophysics, Troy, NY, USA). Briefly, the endothelial cells are seeded in complete medium into (8W10E -PET arrays Applied Biophysics, NY, USA) each well and allowed them to grow until they reached confluence. The FFA (0.25 mM, a combination of FFA 18:1, FFA 16:0 and FFA 18:0 (2:1:1)) was applied for 24 hours before the barrier disruption was initiated by addition of recombinant human thrombin.

Proliferation

To investigate the proliferative effect of FFA treatment on hPASMCs, the following protocol was applied (Biasin et al., 2014): 10 000 hPASMCs were seeded in 96-well plates; the following day the cells were starved (VascuLife® Basal Medium, 0% FCS, 0.2% antibiotic/antimycotic) or kept under control conditions (VascuLife® Basal Medium with 5% FCS; LifeLine Technology, Walkersville) for 12 h. Afterwards, platelet-derived growth factor (PDGF)-BB was added and the proliferation of hPASMCs was determined by [3H] thymidine (BIOTREND Chemikalien GmbH) incorporation, after 24 h of incubation, as an index of DNA synthesis and measured as radioactivity by scintillation counting (Wallac 1450 MicroBeta TriLux Liquid Scintillation Counter and Luminometer). To investigate the effect of FFA (0.25 mM, a combination of oleate, FFA 16:0 and FFA 18:0 (2:1:1)) on hPASMCs, the same number of cells was seeded and after 12 h of starvation, FFA and vehicle were added and the proliferation of hPASMCs was determined as aforementioned. All experiments were performed in quadruplicate.

DAF-DM-mediated nitric oxide measurement

Measurements were performed as previously described[43]. hPAECs were seeded in gelatin-coated dark 96-well plates, starved for 2 h with Ringer's solution and loaded with 10 μm 4-Amino-5-Methylamino-2′,7′-Difluorofluorescein Diacetate (DAF-FM) for 30 min at 37°C. The cells were stimulated with 5 μM acetylcholine (ACh) for the induction of nitric oxide measurement on CLARIOstar Plus (BMG Labtech, Ortenberg, Germany) at Ex/Em = 495/515 nm. All the assays were performed in quadruplicate and normalized to protein content.

Plasma liquid chromatography–mass spectrometry metabolomics

Metabolites were analysed by targeted hydrophilic interaction liquid chromatography–high resolution mass spectrometry (HILIC-HRMS) metabolomics according to Bajad et al.[46] as described previously[47,48]. Samples were processed according to Yuan et al.[49].

Samples from Graz were aliquoted and stored at the Biobank Graz. On the day of the processing they were thawed in water ice bath on a slow rotary shaker (300 rpm) in < 10 min and vortexed shortly.

Aliquots of 100 µl were precipitated in LoBind Eppendorf tubes with 400 µl cold methanol (-80°C for

at least 4 h, kept on dry ice) and vortexed shortly. After the overnight precipitation at –80 °C the samples

were centrifuged for 10 min at 14.000 g at 4°C and supernatants transferred to fresh LoBind Eppendorf

tubes. Supernatants were dried under nitrogen flow and stored at –80°C until all batches of the cohort

were finished. Extracts were reconstituted in 100 µl 30% methanol/H_2O, vortexed for 45 s and

centrifuged for 5 min at 14.000 g at 4°C. The supernatant was transferred into autosampler vials, and

equal aliquots from all samples were pooled for quality control (QC). All ready-to-measure extracts

were refrozen at –80°C prior to measurement. Every 24 h samples were freshly thawed at RT, vortexed,

spun down and added to the autosampler at 4°C.

Measurements were made in independent runs per cohort with samples in randomized order,

interspaced by according blanks, pooled QC samples and UltimateMix (UM, mix described previously

(Vogel et al., 2019)). Pooled QC samples were generated independently for cohort 1 and 2, while QC

was mixed for cohort 3 and 4. Cohorts 1 and 2 were extracted and measured in 1 batch, while cohorts

3 and 4 were randomly divided into 6 batches for sample extraction and measured with daily thawed

extracts to reduce metabolite degradation.

Extracts were measured with a Dionex Ultimate 3000 high-performance liquid chromatography

(HPLC) setup (Thermo Fisher Scientific, USA) equipped with a NH_2-Luna HILIC analytical column

and crudcatcher with an injection volume of 10 µl and a 37 min gradient from aqueous acetonitrile

solution [(5% acetonitrile v/v), 20 mM ammonium acetate, 20 mM ammonium hydroxide, pH 9.45] as

eluent A (LMA) to acetonitrile as eluent B (LMB). Mass spectrometric detection was carried out with

a Q-Exactive[TM] system (Thermo Fisher Scientific). Electrospray ionization (ESI) was used for negative

and positive ionization and masses between 70 and 1050 m/z were detected.

Raw data were converted to mzXML using msConvert (ProteoWizard Toolkit v3.0.5), and

target metabolites were extracted using the in-house developed tool PeakScout. Spectrum slices were

presented around the exact target mass (± 50 ppm) and retention time (± 3 min) in accordance with the

standards described by Sumner et al.[50]. For each target metabolite all peak area integrations were

manually confirmed in each sample. Molecular masses of target metabolites were taken from literature

and available online databases (HMDB, KEGG, Metlin)[51–53]. In addition, pure substances of all

hydrophilic metabolites and selected lipophilic metabolites were run on the same system to obtain

accurate reference retention times and fragmentation spectra.

The analytical quality of all targeted metabolites was strictly graded to be suitable for

multivariate analysis and univariate analysis using the following parameters: deviation from target mass

< 5 ppm, mass difference range < 10 ppm, retention time standard deviation < 0.75 min, percentage of

missing values < 30%, relative standard deviation in QC after drift correction <30%, and blank load in

QC < 30%. Of 164 included metabolites, 11 metabolites were considered unsuitable for ROC analysis

due to lower signal intensity and lower consistency in repeated sample measurements (controls in
cohorts 3 and 4).

Analytical quality of samples, blanks, QC, and UM was graded by sample median, peak shapes,
retention time shifts, percentage of missing values < 30%, and position in the PCA scores plot. From
cohort 2, the first two UM and from cohort 4 the last four QC did not meet the quality criteria and were
therefore excluded.

Statistical analysis

Data visualisation and statistical analysis were performed with R v4.0.2 (R Core Team, 2020)
(using the packages readxl, openxlsx, stringr, dplyr, tidyr, doParallel, statTarget, car, colorspace,
RColorBrewer, ggplot2, ggforce, ggpmisc, ggpubr, scales, grid, ellipse, correlation, dendsort,
pheatmap, nlme, emmeans, missMDA, FactoMineR, mixOmics, MetaboAnalystR 3.0.3, survival,
survminer, pROC, caret, patchwork) and TIBCO Spotfire v11.8.0, TIBCO, Palo Alto, CA. Graphpad
Prism v9 has been used to assess differences in the *in vitro* experiments.

Typically, MS results are relative and only comparable within the same run. However, recent
advances in drift correction allow to merge data for joint analysis. Peak areas without drift correction
were log_{10}-transformed prior to all further analysis. The drift correction was based on the RF driven
algorithm that used QC measurements to model batch effects and drift for each metabolite with
statTarget::shiftCor(., Frule = 0.7, ntree = 500, impute = "KNN", coCV = 100, QCspan = 0, degree
= 2) [54]. The imputed, drift-corrected data were multiplied by 10^3 to make the numbers more readable
after log_{10}-transformation. In the drift corrected, log_{10}-transformed data all imputed values were
removed and data was trimmed by median absolute deviation (MAD) score[55], assuming a normal
distribution (multiplication with 1.4826). Strong single outliers were removed with a very conservative
threshold of having an absolute MAD score > 4 (165 single values in 65 metabolites). Data for all
metabolites and samples is provided in Supplementary Data 1 with and without drift correction.

In order to ensure validity of drift correction and subsequent results, each measurement run was
first analysed independently with unsupervised multivariate (iPCA), supervised multivariate (OPLS-
DA) and univariate on log_{10}-transformed data without drift correction (see Fig. S1). Next, drift
corrected, log_{10}-transformed data from all runs was jointly analysed with the same methods. The drift
correction successfully removed the significant difference between measurement runs and notably
reduced the technical variability in all metabolites (Fig. S2). Additionally, no difference was observed
based on center or sample material type (Fig. S2). Replicate measurements of samples in different runs
were average on drift corrected data to yield one metabolome per patient for subsequent analysis one
metabolome per patient.

All reported p-values were adjusted for multiple testing according to Benjamini–Hochberg

(BH) denoted as p_{BH} (*stats::p.adjust()*)[56]. Distribution and scedasticity were investigated with

Kolmogorov–Smirnov test (*stats::ks.test()*) and Brown–Forsythe Levene-type test (*car::leveneTest()*)

[57], respectively. After log_{10}-transformation data was mostly normally distributed with 91% of all

metabolites without drift correction and 99% of all metabolites with drift correction testing not

significant ($p_{BH} > 0.05$). Analog, data was mostly homoscedastic with 79% without drift correction and

80% with drift correction of all metabolites testing not significant ($p_{BH} > 0.05$).

For iPCA missing values were imputed with *missMDA::imputePCA(., ncp = 10)*[58] and analysis

was performed scaled and centred to unit variance (z-scaled) with *mixOmics::ipca(., scale = TRUE,*

ncomp = 2, mode = "deflation")[59].

For OPLS-DA missing values were imputed with *MetaboAnalystR::ImputeMissingVar(.,*

method = "knn_var")[60], data was scaled and centred to unit variance (z-scaled) with

MetaboAnalystR::Normalization(…, "AutoNorm") and models were calculated with

MetaboAnalystR::OPLSR.Anal(., reg = TRUE) with a standard 7-fold cross-validation for the factor

disease. Model stability was additionally verified with 1000 random label permutations by

MetaboAnalystR::OPLSDA.Permut(., num = 1000).

Pearson correlation were calculated for each metabolite (drift corrected, log_{10}-transformed data)

against each numeric clinical parameter (untransformed) with *correlation::correlation()*[61]. Results were

filtered to retain only metabolites and clinical parameters with at least one significant correlation

($p_{BH} < 0.05$). Retained correlations were clustered by Lance-Williams dissimilarity update with

complete linkage using *stats::dist()* and *stats::hclust()*. Dendogram were sorted with

dendsort::dendsort()[62] at every merging point according to the average distance of subtrees and plotted

at the corresponding heat maps of Pearson R with *pheatmap::pheatmap()*[63].

For univariate analysis of significant changes within each metabolite for the factor *disease* (i.e.

PH vs. HC/DC) generalized least squares models were fitted with *nlme::gls()*[64,65] without confounders

and with potential confounders (age, sex, BMI) by maximum likelihood. For analysis within each cohort

log_{10}-transformed data was used, for joint analysis over all cohorts drift corrected, log_{10}-transformed

data was used, thus constituting a nonlinear approach. The three most common potential confounders

(age, sex, BMI) were added stepwise in all possible combinations and model performances were

compared within each metabolite by lower AIC (Akaike information criterion; relative estimate of

information loss), higher log-likelihood (goodness of fit), significance in log-likelihood ratio test

comparing two models, quality of Q-Q plots, randomness in residual and direct comparison of t-ratios.

All models with any confounder combination showed significant influence ($p < 0.01$) on selected few

metabolites (13–39). The model with age + sex impacted most metabolites. However, a direct

comparison of t-ratio revealed a very small impact of age or sex correction on results, and according to
model parsimony models without confounders were reported throughout.

FFA/lipid-ratios were calculated with FFAs in the numerator and lipids in the denominator. The
numerators were all possible, summed (not weighed) combinations of up to six FFA from 11 FFAs
(most significant in univariate analysis PH versus HC/DC and best analytical quality): FFA C15:0,
FFA C16:2, FFA C16:1, FFA C17:1, FFA C17:0, FFA C18:3, FFA C18:2, FFA C18:1, FFA C19:1,
FFA C20:5 and FFA C20:1. The denominators were all possible, summed (not weighed) combinations
of up to four lipids from eight lipids (no significant change in univariate analysis and best analytical
quality): LPC 18:2, LPC 18:1, PC 36:4, PC 38:6, SM 34:2, SM 36:2, LPE 16:0, and LPE 18:1. The
combination of all possible summed FFA numerator and summed lipid denominator yielded a total of
246 842 different FFA/lipid-ratios. All used FFA and lipids had no missing values. The technical
variability RSD in QC was calculated for each FFA/lipid-ratio following the rules of error propagation
from the single metabolites RSD of QC in drift corrected, log_{10}-transformed data. All FFA/lipid-ratios
were calculated once without and once with drift correction (both log_{10}-transformed). Diagnostic
performance was tested by ROC analysis with *pROC::roc(..., algorithm = 2)*[66] based on our training
cohort. Test data like in machine learning approaches was not needed here because ratios are directly
calculated without any model training. Therefore logistic regression was performed fitting training data
with *stats::glm(..., family = "binomial")*. The performance was evaluated on the validation cohort
using *pROC::roc()*. The optimal threshold was determined with *pROC::coords(..., ,best.method =*
"closest.topleft") to determine sensitivity and specificity.

Survival analysis used either times since sampling or times since diagnosis defining confirmed death as
endpoint while censoring all others at time of last known follow-up. Impact of all relevant clinical
parameters (untransformed), all single metabolites (drift corrected, log_{10}-transformed data) and best
performing FFA/lipid-ratios (log_{10}-transformed data without drift correction) was analysed. FPHR4p
scores were inverted so that higher values represent higher mortality risk. Numerical parameters were
split into *high* and *low* with maxstat as optimal cut-off for survival prediction as determined by
survminer::surv_cutpoint(..., minprop = 0.3)[67]. Kaplan–Meier curves were fitted for each category with
survival::survfit()[68], differences were tested with *survminer::ggsurvplot()* and plots with time since
diagnosis were truncated at 15 years for better comparability with times since baseline (i.e. time since
sampling). The Cox HR analysis[69] was calculated with *survminer::coxph()* for the confounders (age,
sex, BMI), the COMPERA 2.0 score, FPHR4p, and RATIO1 alone or in combinations. Numeric factors
were categorized into *high* and *low* same as for Kaplan-Meier curves. The combination of RATIO1
with the FPHR4p or COMPERA 2.0 score was done additively with the same weighting on scaled
values from 0 to 1, rescaling after addition.

Data visualisation and calculation of the machine learning and Cox
HR analysis was performed with Python 3.9 (using the packages pandas, numpy, seaborn, sklearn,
matplotlib, xgboost)[70–73].

For machine learning, the package sklearn[74] was used for the random forest (RF) and package
xgboost for the XGBoost[19] implementation. Data was normalized with mean 0 and variance 1. A
hyperparameter search for *number of trees {101, 301, 1001, 2001, **3001**} and depth {5, 10, 100, 200,*
***300}* for RF and *eta {0.1, **0.01**, 0.001}, depth {**5**, 10, 100, 200, 300}* and *n_estimators {101, 301, 1001,*
*2001, **3001**}* for XGBoost was conducted with finally used hyperparameters highlighted in bold. Models
were trained on trainings data with five random splits (stratified by group, age, sex) into 80% training
data tested against the remainder 20% data from the split. Models were validated with the external
validation cohort.

Language editing was aided by the artificial intelligence tool https://instatext.io/ (accessed February
2023).

Supplemental Information

690   Supplemental Information can be found attached to this publication.

Materials Availability

692   This study did not generate new unique reagents.

Data and Code Availability

The author declare that all data supporting the findings in this study are available in the online
supplementary data 1 and online repositories. Mass spectrometric data have been deposited in
https://zenodo.org under doi: 10.5281/zenodo.7857706. Data is provided de-identified and is available
immediately after publication with no end for those who wish to access the data for any purpose. The
provided *Sample_Name* in the online supplementary data 1 links to the file names in the online
repository and are unsuitable to identify single patients. The primary key is only known to part of the
study team. Due to the sensitive nature of potentially identifying information exact age can only be
provided upon reasonable request

Author contributions

Conceptualisation, NB, BMN, TP, HO, AO; Data curation, NB, BMN, EZ, HL, UB, HO, AO;
Formal analysis, NB, BMN, EZ, HL, UB, HO, AO; Funding acquisition, NB, TP, HO, AO;
Investigation, NB, BMN, EZ, VF, CN, VB, HO, AO; Methodology, NB, BMN, EZ, CN, AO, HO;
Project administration, NB, BMN, UB, VF, KH, SU, TJL, HO, AO; Resources, NB, BN, EZ, CM, HL,
UB, KH; SU, TJL, TP, HO, AO; Software, NB, HL; Supervision, NB, EZ, UB, HO, AO; Validation,

NB, BN, EZ, HL, VF, CN, VB, SU, TJL, HO, AO; Visualisation, NB, BMN, HL, CN, VB, AO; Writing

– original draft, NB, BAM, HO, AO; Writing – Review & Editing, all authors;

Acknowledgements

We are very grateful for the excellent technical assistance from Elisabeth Blanz, Sabine

Halsegger, Daniela Kleinschek, Jessica Schweiger, Yasemin Gassner, Gert Trausinger and Edgar

Gander. We express our heartfelt gratitude to Saskia Trescher, Pablo López-García, Sophie Narath,

Michael Pienn and Peter Wolf for their valuable discussions and helpful advices.

Funding

NB, TP disclose that part of this work has been carried out with the K1 COMET Competence

Center CBmed, which is funded by the Federal Ministry of Transport, Innovation and Technology; the

Federal Ministry of Science, Research and Economy; Land Steiermark (Department 12, Business and

Innovation); the Styrian Business Promotion Agency; and the Vienna Business Agency. The COMET

program is executed by the Österreichische Forschungsförderungs GmbH FFG. VB is supported by the

Austrian Science Foundation (FWF, T1032-B34).

Competing interests

Several authors (NB, CM, AO, BMN, HO) are inventors of the patent "*Biomarker for the*

diagnosis of pulmonary hypertension (PH)" WO2017153472A1 (priority date 09.03.2016, granted in

US, KR, JP, pending in CA, EP, AU) being jointly held by CBmed Gmbh, Joanneum Research

Forschungsgesellschaft mbH, Medical University Graz and Ludwig Boltzmann Gesellschaft GmbH.

The authors received no personal financial gain from the patent.

During work on this publication NB was partially employed at CBmed GmbH. TP is chief

scientific officer (CSO) of CBmed GmbH. EZ and CM were employed at Joanneum Research

Forschungsgesellschaft mbH. The employing companies provided support in the form of salaries,

materials and reagents but did not have any additional role in the study design, data collection and

analysis, decision to publish, or preparation of the manuscript.

VF received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or

educational events from Janssen, Chiesi, BMS, and Boehringer Ingelheim and support for attending

meetings, and/or travel from Janssen, MSD, and Boehringer Ingelheim outside the submitted work.

CN received support for attending meetings, and/or travel from Boehringer Ingelheim and

Inventiva pharma outside the submitted work.

BAM reports personal fees from Actelion Pharmaceuticals, Tenax and Regeneron, grants from

Deerfield Company, NIH (5R01HL139613-03, R01HL163960, R01HL153502, R01HL155096-01),

Boston Biomedical Innovation Ceter (BBIC), Brigham IGNITE award, Cardiovascular Medical

research Education Foundation outside the submitted work. BAM reports patent PCT/US2019/059890

(pending), PCT/US2020/066886 (pending) and #9,605,047 (granted) not licensed and outside the

submitted work.

SU received grants from the Swiss National Science Foundation, Zürich and Swiss Lung

League, EMDO-Foundation, Orpha-Swiss, Janssen and MSD all unrelated to the present work. SU

received consultancy fees and travel support from Orpha-Swiss, Janssen, MSD and Novartis unrelated

to the present work.

TJL reports grants for his institution from Acceleron Pharma, Gossamer Bio, Janssen-Cilag,

and United Therapeutics; personal fees and non-financial support from Acceleron Pharma,

AstraZeneca, Boehringer Ingelheim, Gossamer Bio, Ferrer, Janssen-Cilag, MSD, Orphacare, and Pfizer

outside the submitted work.

KH is a consultant at Medtronic Österreich GmbH outside the submitted work.

TP reports grants from AstraZeneca, Novo Nordisk, Sanofi paid to the Medical University of

Graz outside the submitted work. TP reports personal fees and nonfinancial support from Novo Nordisk

and Roche Diagnostics outside the submitted work.

HO reports grants from Bayer, Unither, Actelion, Roche, Boehringer Ingelheim, and Pfizer. HO

reports personal fees and nonfinancial support from Medupdate and Mondial, AOP, Bayer, Actelion,

Pfizer, Ferrer, Novartis, Astra Zeneca, Boehringer Ingelheim, Chiesi, Menarini, MSD, and GSK outside

the submitted work.

AO received honoraria for presentations and support for attending meetings, and/or travel from

MSD outside the submitted work.

No conflict of interest, financial or otherwise, are declared by the authors HL and UB.

References

1.   Humbert, M. *et al.* 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* **61**, (2023).

2.   Hoeper, M. M. *et al.* A global view of pulmonary hypertension. *Lancet Respir Med* **4**, 306–322 (2016).

3.   Vachiéry, J.-L. *et al.* Pulmonary hypertension due to left heart disease. *Eur Respir J* **53**, (2019).

4.   Nathan, S. D. *et al.* Pulmonary hypertension in chronic lung disease and hypoxia. *Eur Respir J* **53**, (2019).

5.   Maron, B. A. *et al.* Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. *Lancet Respir Med* **8**, 873–884 (2020).

6.   Douschan, P. *et al.* Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. *Am J Respir Crit Care Med* **197**, 509–516 (2018).

7.   Farber, H. W. *et al.* Five-Year outcomes of patients enrolled in the REVEAL Registry. *Chest* **148**, 1043–54 (2015).

8.   Zelt, J. G. E. *et al.* Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. *Eur Respir J* **59**, (2022).

9.   Kräuter, C. *et al.* Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI. *Magn Reson Imaging* **88**, 132–141 (2022).

10.   Brittain, E. L. *et al.* Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. *Circulation* **133**, 1936–1944 (2016).

11.   Hemnes, A. R. *et al.* Human PAH is characterized by a pattern of lipid-related insulin resistance. *JCI Insight* **4**, (2019).

12.   Lewis, G. D. *et al.* Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. *J Am Coll Cardiol* **67**, 174–189 (2016).

13.   Rhodes, C. J. *et al.* Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. *Circulation* **135**, 460–475 (2017).

14.   Nagy, B. M. *et al.* Importance of kynurenine in pulmonary hypertension. *American Journal of Physiology-Lung Cellular and Molecular Physiology* **313**, L741–L751 (2017).

15.   Nagy, B. M. *et al.* No indication of insulin resistance in idiopathic PAH with preserved physical activity. *European Respiratory Journal* vol. 55 Preprint at https://doi.org/10.1183/13993003.01228-2019 (2020).

16.   Wertheim, B. M. *et al.* Proline and glucose metabolic reprogramming supports vascular endothelial and medial biomass in pulmonary arterial hypertension. *JCI Insight* **8**, (2023).

17.   Breiman, L. Random forests. *Mach Learn* **45**, 5–32 (2001).

18.   Breiman, L., Friedman, J. H. (Jerome H.), Olshen, R. A. & Stone, C. J. *Classification and regression trees*. (1984).

19.   Chen, T. & Guestrin, C. XGBoost. in *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining* 785–794 (ACM, 2016). doi:10.1145/2939672.2939785.

20.   Boucly, A. *et al.* Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *European Respiratory Journal* **50**, (2017).

21.   Hoeper, M. M. *et al.* COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. *European Respiratory Journal* **60**, (2022).

22.   Bourgin, M. *et al.* Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients. *Aging* **13**, 20860–20885 (2021).

23.   Kibe, R. *et al.* Upregulation of colonic luminal polyamines produced by intestinal microbiota delays senescence in mice. *Sci Rep* **4**, 4548 (2015).

24.   Willeit, P. *et al.* Asymmetric dimethylarginine and cardiovascular risk: Systematic review and meta-analysis of 22 prospective studies. *J Am Heart Assoc* **4**, (2015).

25.   Delcroix, M. & Howard, L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. *European Respiratory Review* **24**, 621–629 (2015).

26.   Kovacs, G. *et al.* An official European Respiratory Society statement: pulmonary haemodynamics during exercise. *European Respiratory Journal* **50**, 1700578 (2017).

27.   Paulin, R. & Michelakis, E. D. The Metabolic Theory of Pulmonary Arterial Hypertension. *Circ Res* **115**, 148–164 (2014).

28.   Talati, M. H. *et al.* Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. *Am J Respir Crit Care Med* **194**, 719–28 (2016).

29.   Hemnes, A. R. *et al.* Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med* **189**, 325–34 (2014).

30.   Harbaum, L. *et al.* Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med* **205**, 1449–1460 (2022).

31.   Rhodes, C. J. *et al.* Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med* **205**, 1102–1111 (2022).

32.   Bhatt-Wessel, B., Jordan, T. W., Miller, J. H. & Peng, L. Role of DGAT enzymes in triacylglycerol
metabolism. *Arch Biochem Biophys* **655**, 1–11 (2018).
33.   Chambers, K. T. *et al.* Myocardial Lipin 1 knockout in mice approximates cardiac effects of human LPIN1
mutations. *JCI Insight* **6**, (2021).
34.   Reue, K. The lipin family: mutations and metabolism. *Curr Opin Lipidol* **20**, 165–70 (2009).
35.   Takeuchi, K. & Reue, K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes
in triglyceride synthesis. *Am J Physiol Endocrinol Metab* **296**, E1195-209 (2009).
36.   Kovacs, G. *et al.* Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective
study. *Eur Respir J* **50**, (2017).
37.   Kovacs, G. *et al.* Severe Pulmonary Hypertension in COPD: Impact on Survival and Diagnostic
Approach. *Chest* **162**, 202–212 (2022).
38.   Haudum, C. W. *et al.* Cohort profile: 'Biomarkers of Personalised Medicine' (BioPersMed): a single-
centre prospective observational cohort study in Graz/Austria to evaluate novel biomarkers in
cardiovascular and metabolic diseases. *BMJ Open* **12**, e058890 (2022).
39.   Galiè, N. *et al.* 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:
The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European
Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for
European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung
Transplantation (ISHLT). *Eur Respir J* **46**, 903–75 (2015).
40.   Hoffmann, J. *et al.* Distinct differences in gene expression patterns in pulmonary arteries of patients with
chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension.
Am J Respir Crit Care Med **190**, 98–111 (2014).
41.   Nagaraj, C. *et al.* Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may
depend on p22phox. *Eur Respir J* **50**, (2017).
42.   Papp, R. *et al.* Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary
arterial hypertension. *Eur Respir J* **53**, (2019).
43.   Skofic Maurer, D. *et al.* Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human
Pulmonary Arteries. *Cells* **9**, (2020).
44.   Stulnig, G. *et al.* Docosahexaenoic acid (DHA)-induced heme oxygenase-1 attenuates cytotoxic effects
of DHA in vascular smooth muscle cells. *Atherosclerosis* **230**, 406–413 (2013).
45.   Kikuchi, N. *et al.* Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension:
Possible Novel Therapeutic Target. *Circulation* **138**, 600–623 (2018).
46.   Bajad, S. U. *et al.* Separation and quantitation of water soluble cellular metabolites by hydrophilic
interaction chromatography-tandem mass spectrometry. *J Chromatogr A* **1125**, 76–88 (2006).
47.   Fröhlich, E. E. *et al.* Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut
microbiota-brain communication. *Brain Behav Immun* **56**, 140–155 (2016).
48.   Mueller, K. M. *et al.* Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and Hfd-Induced
Obesity, and Impairs the Feeding-Fasting Transition. *Diabetes* **66**, 272–286 (2017).
49.   Yuan, M., Breitkopf, S. B., Yang, X. & Asara, J. M. A positive/negative ion-switching, targeted mass
spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. *Nat Protoc*
7, 872–81 (2012).
50.   Sumner, L. W. *et al.* Proposed minimum reporting standards for chemical analysis Chemical Analysis
Working Group (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics* **3**, 211–221 (2007).
51.   Guijas, C. *et al.* METLIN: A Technology Platform for Identifying Knowns and Unknowns. *Anal Chem*
90, 3156 (2018).
52.   Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for
gene and protein annotation. *Nucleic Acids Res* **44**, D457–D462 (2016).
53.   Wishart, D. S. *et al.* HMDB 4.0: The human metabolome database for 2018. *Nucleic Acids Res* **46**, D608–
D617 (2018).
54.   Luan, H., Ji, F., Chen, Y. & Cai, Z. statTarget: A streamlined tool for signal drift correction and
interpretations of quantitative mass spectrometry-based omics data. *Anal Chim Acta* **1036**, 66–72 (2018).
55.   Leys, C., Ley, C., Klein, O., Bernard, P. & Licata, L. Journal of Experimental Social Psychology Detecting
outliers : Do not use standard deviation around the mean, use absolute deviation around the median.
Experimental Social Psychology 4–6 (2013).
56.   Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach
to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* **57**, 289–300
(1995).
57.   Brown, M. B. & Forsythe, A. B. Robust Tests for the Equality of Variances. *J Am Stat Assoc* **69**, 364
(1974).

58.   Husson, F. & Josse, J. missMDA: Handling Missing Values with Multivariate Data Analysis. *R package*
885   *version 1.8.2.* Preprint at http://cran.r-project.org/package=missMDA (2015).
886   59.   Rohart, F., Gautier, B., Singh, A. & Lê Cao, K.-A. mixOmics: An R package for 'omics feature selection
887   and multiple data integration. *PLoS Comput Biol* **13**, e1005752 (2017).
888   60.   Pang, Z., Chong, J., Li, S. & Xia, J. MetaboAnalystR 3.0: Toward an Optimized Workflow for Global
889   Metabolomics. *Metabolites* **10**, 186 (2020).
890   61.   Makowski, D., Ben-Shachar, M., Patil, I. & Lüdecke, D. Methods and Algorithms for Correlation
891   Analysis in R. *J Open Source Softw* **5**, 2306 (2020).
892   62.   Sakai, R. & Biederstedt, E. dendsort: modular leaf ordering methods for dendrogram representations in
893   R. Preprint at https://doi.org/10.12688/f1000research.4784.1 (2021).
894   63.   Kolde, R. pheatmap: Pretty Heatmaps. *R package version 1.0.12* Preprint at https://CRAN.R-
895   project.org/package=pheatmap (2019).
896   64.   Pinheiro, J., Bates, D. & R Core Team. nlme: Linear and Nonlinear Mixed Effects Models. Preprint at
897   https://CRAN.R-project.org/package=nlme (2022).
898   65.   Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D. & R Core Team. nlme: Linear and Nonlinear Mixed Effects
899   Models. *R package version 3.1-122* vol. 3 57 Preprint at http://cran.r-project.org/package=nlme (2015).
900   66.   Robin, X. *et al.* pROC: An open-source package for R and S+ to analyze and compare ROC curves. *BMC*
901   *Bioinformatics* **12**, 77 (2011).
902   67.   Kassambara, A., Kosinski, M. & Biecek, P. survminer: Drawing Survival Curves using 'ggplot2'. Preprint
903   at https://CRAN.R-project.org/package=survminer (2021).
904   68.   Therneau, T. M. Package for Survival Analysis in R. Preprint at https://CRAN.R-
905   project.org/package=survival (2021).
906   69.   Cox, D. R. Regression Models and Life-Tables. *Journal of the Royal Statistical Society: Series B*
907   *(Methodological)* **34**, 187–202 (1972).
908   70.   Harris, C. R. *et al.* Array programming with NumPy. *Nature* **585**, 357–362 (2020).
909   71.   McKinney, W. Data Structures for Statistical Computing in Python. in *PROC. OF THE 9th PYTHON IN*
910   *SCIENCE CONF. (SCIPY 2010)* 56–61 (2010).
911   72.   Waskom, M. *et al.* mwaskom/seaborn: v0.8.1 (September 2017). Preprint at
912   https://doi.org/10.5281/zenodo.883859 (2017).
913   73.   Hunter, J. D. Matplotlib: A 2D Graphics Environment. *Comput Sci Eng* **9**, 90–95 (2007).
914   74.   Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research* **12**,
915   2825–2830 (2011).
916
917
918

 Supplementary Figures

Fig. S1. PH is associated with a strong metabolic shift in every measurement run. (A) iPCA scores plot representing the metabolic profile of each sample as a dot. The proximity of the dots indicates the similarity of the subjects' metabolomes. Clear group separation by PH is visible along the first and or second component for each run and when all runs are jointly analyzed. **(B)** To A corresponding loadings plot in which each dot represents the contribution of the metabolite to the group separation observed in the scores plot. Free fatty acids (FFA, yellow circles) strongly drive the group separation and are increased in PH patients. **(C)** OPLS-DA maximizes the group difference from PH to HC/DC and the resulting scores plot represents, as in A, with dots the metabolome of each subjects. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. The

difference between the metabolome of PH and HC/DC was significant ($Q^2 > 50\%$, $p < 0.001$). **(D)** Volcano plot of univariate analysis highlighting significant ($p_{BH} < 0.05$, grey horizontal line) and strong (absolute contrast ratio > 0.25, grey vertical lines) increase in FFAs. For all methods 164 known metabolites and all samples from the measurement run per cohort ($n_1 = 16$, $n_2 = 33$, $n_3 = 118$, $n_4 = 109$) on log_{10}-transformed was used. In run 4 measurement all HC samples from run 3 were repeated to evaluate reproducibility of samples across measurement runs.

Fig. S2. Drift correction improves data quality enabling a unified analysis of all 4 measurement runs. (A, B) Plot of the sample's median signal intensity of all metabolites versus the sequence of measurement with measurements runs being separated by vertical black lines. **(A)** The QC samples (grey x) fluctuate within each measurement (= drift), while the batch effect is well visible as signal intensity jumps between the measurements. **(B)** Drift

correction with an RF-based algorithm on QC samples removed drift and batch effects from the median sample intensity. **(C, E, G, H, I, J)** iPCA scores plots plot representing the metabolic profile of each sample as a dot. The proximity of the dots indicates the similarity of the metabolomes. Lines connect replicate measurements from same samples. Note **(C, G, H)** are the same iPCA model highlighting different biological factors. Analog **(E, I, J)** are the same iPCA model. **(C)** A clear group separation by measurement run is well visible between all 4 runs, with runs 3 and 4 being more similar due to the back to back measurement and shared HC and QC samples. **(D)** Drift correction removes the separation by measurement run. (D, F) OPLS-DA maximizes the differences between runs 1 to 4 and the resulting scores plot represents, as in C, with dots the metabolome of each sample. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. **(D)** All 4 measurement runs were highly significantly ($Q^2 > 50\%$, $p < 0.001$) different before drift correction and **(F)** become non-significant after drift correction. **(G, I)** The observed group separation by sample origin (study center) before drift correction was significantly reduced after drift correction. **(H, J)** The observed group separation by sample material type before drift correction was significantly reduced after drift correction. **(K)** The strong reduction of the technical variability over all 4 runs after drift corrections shows how well the RF-based algorithm reduced technical noise. All plots are based on 164 known metabolites and all samples from the measurement run per cohort ($n_1 = 16$, $n_2 = 33$, $n_3 = 118$, $n_4 = 109$). A, C, D, G, H used *log₁₀*-transformed. B, E, F, I, J used *log₁₀*-transformed, drift corrected data.

Fig. S3. Selected metabolites correlate with clinical parameters in the training cohort. (A) Volcano plot of all pairwise Pearson correlations of all 164 metabolites (drift corrected, *log₁₀*-transformed data) versus 43 clinical parameters

highlighting strong (absolute R > 0.5, grey vertical lines) and significant (p_{BH} < 0.05, grey horizontal line) correlations. Based on training cohort (n = 169). **(B)** Heatmaps with hierarchical clustering of the respective metabolite vs. clinical parameter. Pearson correlations were filtered to keep only rows and columns with at least one sig. correlation. Uric acid and creatinine were measured as metabolite and were part of routine hematology. These are accordingly the strongest, most significant correlations. **(C)** Overview of all investigated numeric clinical parameters correlated in (A, B) with all metabolites, listing their short names, explanations and units.

Fig. S4. RF and XGBoost perform similarly with and without drift correction. ROC plots within the training cohort (n = 169, solid lines) and the validation cohort (n = 64, dashed lines) with their 95% confidence intervals as ribbons. For modelling, the training cohort was randomly split into 80% training and 20% testing data. The split was repeated five times without overlap of test data for cross-validation. Top row shows performance of RF without drift correction. The second and third row show the performance of XGBoost with and without drift correction, respectively. Models used either all suitable 153 metabolites (left), only 50 hydrophilic metabolites (middle), or only 103 lipophilic metabolites (right).

Fig. S5. A quarter million of FFA/lipids-ratios could diagnose PH. (A, B, C, D) The histogram of ROC analysis performance AUC for all possible FFA/lipid-ratios exhibits a tight distribution showing that all ratios performed similarly good. Ratios were calculated from 11 different FFA (numerator) and 8 different lipids (denominator). All possible sums for numerator and denominator were tested, limiting to a maximum of 6 FFA in the numerator and 4 lipids in the denominator yielding a total of 246 842 ratios. The grey vertical line marks an AUC of 0.6 as cut-off for minimal diagnostic performance. ROC analysis was based on the training cohort (n = 169) and benchmarked against the validation cohort (n = 64). **(A, C)** Ratios based on not drift corrected, only *log10*-transformed data performed all consistently very well, with most achieving around AUC > 0.8. **(B, D)** Drift correction further slightly improved diagnostic performance of the FAF/lipid ratios. **(A, B)** All samples from the trainings data set (cohort 1, 2, 3 with n = 167) were used. **(C, D)** All samples from the validation data set (cohort 4, n = 64) were used. The distribution of ratio performance between trainings data **(A, C)** and validation data **(B, D)** was similar for all ratios.

(E, F) Direct comparison of ratio performance in trainings data versus validation data in **(E)** *log₁₀*-transformed data and **(F)** *log₁₀*-transformed, drift corrected data shows a very good overlap. The grey zones mark an AUC of 0.6 as cut-off for minimal diagnostic performance. **(G)** The histogram of the calculated technical error ratio for each ratio exhibits a tight distribution around 5% total technical relative variability showing. The grey vertical line marks the maximally acceptable technical variability cut-off for measurement methods in clinical routine laboratories. **(H)** Overview of top performing ratios in both data types and ratio equation of the three overlapping ratios. **(I)** Direct comparison of ratio performance in the training data between both data types shows a very good overlap. The grey zones mark an AUC of 0.6 as cut-off for minimal diagnostic performance.

Fig. S6. RATIO1 predicts survival since diagnosis and improves established clinical scores. **(A)** Cox HR analysis for survival since diagnosis and 95% confidence interval with statistical significance coded as not significant (ns); * p < 0.05; ** p < 0.01; *** p < 0.001. Combining RATIO1 with the FPHHR4p or COMPERA 2.0 increased HR compared with scores or RATIO1 alone. **(B, C, D)** Kaplan–Meier curves for survival since diagnosis by RATIO1 **(B)**, FPHR4p and COMPERA 2.0 **(C)** and RATIO1 combined with FPHR4p or COMPERA 2.0 **(D)**. All cut-offs were optimized with maxstat for both Cox HR analysis and Kaplan–Meier analysis. RATIO1 was based on *log₁₀*-transformed data without drift correction. RATIO1 and scores were combined scaled 0 to 1 to give equal weighing. FPHR4p was inverted so that higher scores also represent higher risk as in COMPERA 2.0 for simpler interpretation.

Fig. S7. Survival analysis of covariates age, sex and BMI. (A) Cox HR analysis for survival since baseline (left) and since diagnosis (right) and the 95% confidence interval with statistical significance coded as not significant (ns); * p < 0.05; ** p < 0.01; *** p < 0.001. Higher age alone and in the tri-factor model was a significant risk factor for both times since baseline and times since diagnosis. BMI was barely significant when modelled alone but not significant in the tri-factor model, while sex being male was slightly elevated but never significant. **(B)** Kaplan–Meier curves of survival times since baseline and since diagnosis by age, sex or BMI. Age and BMI cut-offs were optimized with maxstat for both Cox HR analysis and Kaplan–Meier analysis. Survival of PH patients decreases strongly and significantly for higher age and weakly with higher BMI.

Fig. S8. Further predictors of survival. (A, B) Kaplan–Meier curves analyzing survival times since baseline or since diagnosis for PH patients. The stated cut-off for survival prediction was optimized with maxstat. **(A)** Survival of PH patients significantly decreases with known clinical risk factors such as higher WHO FC classes, lower 6MWD, higher NT-pro-BNP levels, and higher uric acid levels. **(B)** The top two metabolites able to predict survival were ADMA and N-Acetylputrescine (both drift corrected, log_{10}-transformed data) with high levels strongly associated with poor prognosis. All cut-offs were optimized with maxstat for Kaplan–Meier analysis.

Supplementary Tables

935 **Table S1: Subject characteristics with medians ± 95% confidence intervals within measurement runs of the training**

936 **cohort**

	run 1		run 2			run 3		
	HC (n=8)	PH (n=8)	HC (n=12)	DC (n=9)	PH (n=12)	HC (n=45)	DC (n=21)	PH (n=52)
Age at sampling, y	57.0±8.8	58.5±9.0	70.5±10.8	56.0±10.1	63.0±9.3	58.0±2.6	60.0±5.7	66.5±3.7
Female:male (ratio)	7:1 (7:1)	7:1 (7:1)	11:1 (11:1)	7:2 (3.5:1)	11:1 (11:1)	26:19 (1.4:1)	13:8 (1.6:1)	30:22 (1.4:1)
BMI kg/m²	22.6±2.7	24.8±3.4	25.8±3.0	30.7±5.5	25.5±3.5	24.1±1.0	22.5±3.2	25.7±1.3
Diagnosis since y	-	3.0±5.9	-	-	6.0±4.0	-	8.0±2.1	0.0±1.1
Pulmonary hemodynamics from RHC								
mPAP (mmHg) mean pulmonary arterial pressure	-	45.0±7.7	-	-	41.5±5.8	-	22.0±0.8[#]	41.0±3.1
PAWP (mmHg) pulmonary arterial wedge pressure	-	10.0±4.2	-	-	5.5±1.7	-	9.5±0.3[#]	10.0±1.6
CO (L/min) cardiac output	-	4.1±1.6	-	-	4.3±0.8	-	3.9±0.4[#]	4.6±0.5
CI (L/min/m²) cardiac index	-	2.3±0.7	-	-	2.5±0.5	-	2.4±0.3[#]	2.6±0.2
PVR (WU) pulmonary vascular resistance	-	8.3±3.7	-	-	8.9±3.1	-	3.2±0.3[#]	6.0±1.2
RAP (mmHg) right arterial pressure	-	5.0±3.8	-	-	5.0±2.4	-	5.0±1.1[#]	7.0±1.5
Clinical data								
6MWD (m) 6-min walk distance	-	338±96	-	-	431±149	-	454±50	317±32
WHO FC world health organisation functional class	-	3.0±0.6	-	-	3.0±0.5	-	2.0±0.3	3.0±0.2
FEV1 (% predicted) forced expiration 1 s	-	83.0±16.5	-	-	82.5±12.9	-	51.5±12	68.5±6.7
FVC (% predicted) forced vital capacity	-	90.9±18.0	-	-	97.6±14.8	-	63.8±8.2	78.0±6.5
FEV1/FVC (% predicted)	-	73.3±6.0	-	-	78.3±6.5	-	56.3±10.3	73.2±3.9
TLC (% predicted) total lung capacity	-	95.7±12.5	-	-	103.1±9.4	-	103.0±13.2	92.0±5.2
DLCO cSB (% predicted) single-breath CO diffusing capacity, hemoglobin corrected	-	69.5±8.4	-	-	65.4±9.5	-	49.6±9.6	56.4±8.2
DLCO cVA (% predicted) CO diffusing capacity alveolar volume, hemoglobin corrected	-	74.6±14.1	-	-	60.6±20.8	-	70.0±9.6	71.0±7.8
RDW (%) red cell distribution width	-	15.5±1.1	-	-	14.4±0.9	-	14.0±0.9	15.7±1.0
NT-proBNP (pg/mL)	-	508±1197	-	-	263±1122	-	90±50	1100±1112.2
Uric acid (mg/dL)	-	5.7±1.4	-	-	5.7±1.6	-	5.0±0.6	6.2±0.7
Creatinine (mg/dL)	-	0.92±0.17	-	-	1.02±0.19	-	0.80±0.11	1.04±0.17
Bilirubin total (mg/dL)	-	0.61±0.25	-	-	0.57±0.26	-	0.40±0.16	0.70±0.17

937 [#]based on 4 patients, not representative

938 **Table S2: Characteristics of patients with IPAH and healthy donors used for laser capture-microdissection of PA.**

	ID	Age	Sex		ID	Age	Sex	mPAP
	1	[50-59]	male		1	[30-39]	female	50
	2	[70-79]	female		2	[30-39]	female	88
	3	[50-59]	female		3	[18-29]	female	56
	4	[30-39]	male		4	[18-29]	female	69
Donor	5	[18-29]	female	IPAH	5	[50-59]	male	66
	6	[50-59]	male		6	[18-29]	male	74
	7	[18-29]	male		7	[50-59]	male	65
	8	[70-79]	female		8	[30-39]	female	69
	9	[50-59]	female		9	[40-49]	male	96
	10	[50-59]	female		10	[18-29]	female	65

939
940
941 **Table S3: Primers used to assess the expression of listed genes.** Gene name, PubMed Nucleotide accession number used
942 for primer design, forward and reverse primer sequences and the size of the PCR product (in bp) 4 are given. All
943 primers were designed so that the PCR product span at least one exon-exon junction.

Gene	Forward primer	Reverse primer	Product size (bp)
SLC25(A5)	GTTGTCGCAGGTGGACTTCT	CCTTACCCTCACAACCTGGC	71
GPAT1	CTGCTAGGGCAGCAGCG	TGCTGGGATGAAAGTTCTTCTGT	108
GPAT2	CTTCCCTTGAGCAGTCCACG	GCCATGAGAGCCTCACACCA	87
AGPAT1	ACAGAGACACAGCCATCCG	CAAATCCATTCTGGCCACCTCAG	102
LIPIN2	TCTCCGCCTTCCACAGAGAA	CTGCTTAGACGGGGCAAACA	98
DGAT1	CAACTACCGTGGCATCCTG	TTCTCCAGAAATAACCGGGC	72

944
945
946 **Table S4: Characteristics of the hPASMC and hPAEC donors used for in vitro studies.**

	ID	Age	Sex		ID	Age	Sex
	1	[30-39]	male		1	[50-59]	male
	2	[50-59]	female		2	[40-49]	female
hPASMC	3	[30-39]	male	hPAEC	3	[50-59]	female
	4	[30-39]	female		4	[50-59]	male
	5	[18-29]	female				
	6	[30-39]	male				

947
948